个人简历

学习经历：
2000.9-2005.7安徽中医学院，中医临床医学，学士
2005.9-2008.7南方医科大学，药理学，硕士
2009.7-2012.12中山大学，药学院，博士
2013.5-2016.10南方医科大学，药学，博士后
2015.5-2016.6多伦多大学，神经生物学，博士后
主要科研课题：
1.国家自然科学基金青年基金。81301099。FoxO3a转录因子在β淀粉样蛋白诱导的突触损伤中的作用及机制研究。2014.01-2016.12。主持。
2.广东省自然科学基金博士启动基金。S2013040014202。CREB蛋白与FoxO蛋白相互作用在抑郁症发病机制中的作用研究。2013.10-2015.9。主持。

研究领域

研究方向：
神经退行性疾病发病机制及药物筛选
抑郁症发病机制研究及药物筛选

近期论文

代表性论文：
1.WangH,HuangS,YanK,FangX,AbussaudA,MartinezA,SunHS,FengZP.Tideglusib,achemicalinhibitorofGSK3β,attenuateshypoxic-ischemicbraininjuryinneonatalmice.BiochimBiophysActa.2016,1860(10):2076-85.(IF=5.083).
2.ZengB,LiY,NiuB,WangX,ChengY,ZhouZ,YouT,LiuY,WangH*,XuJ*.InvolvementofPI3K/Akt/FoxO3aandPKA/CREBSignalingPathwaysintheProtectiveEffectofFluoxetineAgainstCorticosterone-InducedCytotoxicityinPC12Cells.JMolNeurosci.2016,59(4):567-78.(*co-correspondingauthor,IF=2.353).
3.LiuR#,WangH#,XuB#,ChenW,TurlovaE,DongN,SunCL,LuY,FuH,ShiR,BarszczykA,YangD,JinT,MannucciE,FengZP,SunHS.CerebrovascularSafetyofSulfonylureas:TheRoleofKATPChannelsinNeuroprotectionandtheRiskofStrokeinPatientsWithType2Diabetes.Diabetes.2016;65(9):2795-809.(#Co-firstauthor,IF=8.784).
4.ZhengW#,ChongCM#,WangH#,ZhouX,ZhangL,WangR,MengQ,LazaroviciP,FangJ.ArtemisininconferredERKmediatedneuroprotectiontoPC12cellsandcorticalneuronsexposedtosodiumnitroprusside-inducedoxidativeinsult.FreeRadicBiolMed.2016,97:158-67.(#Co-firstauthor,IF=5.784).
5.WangH,QuirionR,LittlePJ,ChengY,FengZP,SunHS,XuJ,ZhengW.ForkheadBoxOTranscriptionFactorsasPossibleMediatorsintheDevelopmentofMajorDepression.Neuropharmacology.2015,99,527-537.(IF=5.107).
6.ChenQ#,WangH#,LiaoS,GaoY,LiaoR,LittlePJ,XuJ,FengZP,ZhengY,ZhengW.Nervegrowthfactorprotectsretinalganglioncellsagainstinjuryinducedbyretinalischemia-reperfusioninrats.GrowthFactors.2015,33(2):149-59.(#Co-firstauthor,IF=3.386).
7.WangH,LiaoS,GengR,ZhengY,LiaoR,YanF,ThrimawithanaT,LittlePJ,FengZP,LazaroviciP,ZhengW.IGF-1signalingviathePI3K/Aktpathwayconfersneuroprotectioninhumanretinalpigmentepithelialcellsexposedtosodiumnitroprussideinsult.JMolNeurosci.2015,55(4):931-40.(IF=2.757).
8.WangH,WangR,ThrimawithanaT,LittlePJ,XuJ,FengZP,ZhengW.TheNerveGrowthFactorSignalingandItsPotentialasTherapeuticTargetforGlaucoma.BiomedResInt.2014,2014:759473.(IF=2.706).
9.WangH,ZhouX,HuangJ,MuN,GuoZ,WenQ,WangR,ChenS,FengZP,ZhengW.TheroleofAkt/FoxO3aintheprotectiveeffectofvenlafaxineagainstcorticosterone-inducedcelldeathinPC12cells.Psychopharmacology(Berl).2013,228(1):129-41.(IF=4.061).
10.WangH,DuanX,RenY,LiuY,HuangM,LiuP,WangR,GaoG,ZhouL,FengZ,ZhengW.FoxO3anegativelyregulatesnervegrowthfactor-inducedneuronaldifferentiationthroughinhibitingtheexpressionofneurochondrininPC12cells.MolNeurobiol.2013,47(1):24-36.(IF=5.471).
11.WangH,ZhangQ,ZhangL,LittlePJ,XieX,MengQ,RenY,ZhouL,GaoG,QuirionR,ZhengW.Insulin-likegrowthfactor-1inducesthephosphorylationofPRAS40viathePI3K/AktsignalingpathwayinPC12cells.NeurosciLett.2012,516(1):105-9.(IF=2.105).
12.WangH,ZhangQ,WenQ,ZhengY,LazaroviciP,JiangH,LinJ,ZhengW.Proline-richAktsubstrateof40kDa(PRAS40):anoveldownstreamtargetofPI3k/Aktsignalingpathway.CellSignal.2012,24(1):17-24.（IF=4.243）
主要学术任职：
Neuralregenerationresearch青年编委